SI2424495T1 - Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones - Google Patents

Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones Download PDF

Info

Publication number
SI2424495T1
SI2424495T1 SI201031630T SI201031630T SI2424495T1 SI 2424495 T1 SI2424495 T1 SI 2424495T1 SI 201031630 T SI201031630 T SI 201031630T SI 201031630 T SI201031630 T SI 201031630T SI 2424495 T1 SI2424495 T1 SI 2424495T1
Authority
SI
Slovenia
Prior art keywords
composition
tocotrienol
alpha
doa
compound
Prior art date
Application number
SI201031630T
Other languages
Slovenian (sl)
Inventor
Guy M. Miller
Original Assignee
Bioelectron Technology Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioelectron Technology Corporation filed Critical Bioelectron Technology Corporation
Publication of SI2424495T1 publication Critical patent/SI2424495T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to methods of treating Leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones, including alpha-tocotrienol quinone, in order to alleviate symptoms of the disease.

Description

Original document published without description

Claims (14)

ZDRAVLJENJE LEBEROVE HEREDITARNE OPTIČNE NEVROPATIJE IN DOMINANTNE OPTIČNE ATROFIJE S TOKOTRIENOL KINONI EP 2 424 495 B1 PATENTNI ZAHTEVKITREATMENT OF LEEBER HEREDITARY OPTICAL NEVROPATHY AND DOMINANT OPTICAL ATROPHY WITH TOKOTRIENOL KINONS EP 2 424 495 B1 PATENT REQUIREMENTS 1. Sestavek za uporabo pri zdravljenju, preprečevanju ali izboljšanju dominantne optične atrofije (DOA) pri posamezniku, ki trpi za dominantno optično atrofijo (DOA), pri čemer navedeni sestavek vsebuje terapevtsko učinkovito količino spojine izbrane iz skupine, ki jo sestavljajo tokotrienol kinoni in tokotrienol hidrokinoni.A composition for use in the treatment, prevention, or improvement of a dominant optical atrophy (DOA) in an individual suffering from dominant optical atrophy (DOA), said composition comprising a therapeutically effective amount of a compound selected from the group consisting of tocotrienol quinones and tocotrienol hydroquinones. 2. Sestavek po zahtevku 1, za uporabo, kot je definirano v omenjenem zahtevku, kjer je spojina izbrana iz skupine, ki jo sestavljajo alfa-tokotrienol-kinon, beta-tokotrienol-kinon, gama-tokotrienol-kinon in delta-tokotrienol kinon.The composition of claim 1, for use as defined in said claim, wherein the compound is selected from the group consisting of alpha-tocotrienolquinone, beta-tocotrienolquinone, gamma-tocotrienolquinone and delta-tocotrienol quinone. 3. Sestavek po zahtevku 1, za uporabo, kot je definirano v omenjenem zahtevku, kjer je spojina izbrana iz skupina, ki jo sestavljajo alfa-tokotrienol hidrokinon, beta-tokotrienol hidrokinon, gama-tokotrienolni hidrokinon in delta-tokotrienol hidrokinon.The composition of claim 1, for use as defined in said claim, wherein the compound is selected from the group consisting of alpha-tocotrienol hydroquinone, beta-tocotrienol hydroquinone, gamma-tocotrienol hydroquinone and delta-tocotrienol hydroquinone. 4. Sestavek po zahtevku 2, za uporabo, kot je definirano v omenjenem zahtevku, kjer je spojina alfa-tokotrienol kinon.The composition of claim 2, for use as defined in said claim, wherein the compound is alpha-tocotrienol quinone. 5. Sestavek po zahtevku 3, za uporabo, kot je definirano v omenjenem zahtevku, kjer je spojina alfa-tokotrienol hidrokinon.The composition of claim 3, for use as defined in said claim, wherein the compound is alpha-tocotrienol hydroquinone. 6. Sestavek po zahtevku 4, za uporabo, kot je definirano v omenjenem zahtevku, kjer alfa-tokotrienol-kinon vsebuje vsaj 95 mas.% tokotrienolov in tokotrienol kinonov, prisotnih v sestavku.The composition of claim 4, for use as defined in said claim, wherein the alpha-tocotrienolquinone contains at least 95% by weight of tocotrienols and tocotrienol quinones present in the composition. 7. Sestavek po katerem koli od zahtevkov 1 do 6 za uporabo, kot je definirano v omenjenih zahtevkih, ki nadalje obsega oftalmološko sprejemljivo sredstvo ali farmacevtsko sprejemljivo sredstvo.A composition according to any one of claims 1 to 6 for use as defined in the above claims, further comprising an ophthalmologically acceptable agent or a pharmaceutically acceptable agent. 8. Farmacevtski pripravek, ki vsebuje alfa-tokotrienol kinon in oftalmološko ali farmacevtsko sprejemljivo sredstvo, ki vsebuje od 50 mg do 500 mg alfa-tokotrienol kinona za uporabo pri zdravljenju, preprečevanju, ali izboljšanju dominantne optične atrofije (DOA), pri čemer alfa-tokotrienol kinon vsebuje vsaj 50 mas.% tokotrienolov in tokotrienol kinonov, prisotnih v pripravku.A pharmaceutical preparation comprising an alpha tocotrienol quinone and an ophthalmic or pharmaceutically acceptable agent comprising from 50 mg to 500 mg of alpha-tocotrienol quinone for use in the treatment, prevention, or improvement of dominant optical atrophy (DOA), wherein the alpha- tokotrienol quinone contains at least 50% by weight of tocotrienols and tokotrienol quinones present in the preparation. 9. Farmacevtski pripravek po zahtevku 8, za uporabo, kot je definirano v omenjenem zahtevku, kjer alfa-tokotrienol kinon vsebuje vsaj 95 mas.% tokotrienolov in tokotrienol kinonov, prisotnih v pripravku.A pharmaceutical composition according to claim 8, for use as defined in said claim, wherein the alpha-tocotrienol quinone contains at least 95% by weight of tocotrienols and tocotrienol quinones present in the formulation. 10. Sestavek po katerem koli od zahtevkov od 1 do 7 ali farmacevtski pripravek, kot je zahtevano v kateremkoli od zahtevkov 8-9, za uporabo, kot je definirano v omenjenih zahtevkih, kjer je sestavek ali pripravek apliciran preko topičnega, periokularnega ali intraokularnega dajanja.The composition of any one of claims 1 to 7 or the pharmaceutical composition as claimed in any one of claims 8-9 for use as defined in said claims, wherein the composition or preparation is administered via topical, periocular or intraocular administration . 11. Sestavek po katerem koli od zahtevkov od 1 do 7 ali farmacevtski pripravek, kot je zahtevano v kateremkoli izmed zahtevkov 8-9, za uporabo, kot je definirano v omenjenih zahtevkih, pri čemer je sestavek ali pripravek dajan peroralno.A composition according to any one of claims 1 to 7 or a pharmaceutical composition as claimed in any one of claims 8-9 for use as defined in the above claims, wherein the composition or preparation is administered orally. 12. Sestavek po katerem koli od zahtevkov 1 do 7, 10 in 11 ali farmacevtski pripravek, kot je zahtevano v katerem koli od zahtevkov 8-11, za uporabo, kot je definirano v omenjenih zahtevkih, pri čemer ima posameznik, ki trpi zaradi DOA, vsaj eno mutacijo vsaj enega OPA gena, izbranega iz skupine, ki jo sestavljajo OPA1, OPA2, OPA3, OPA4, OPA5, OPA6 in OPA7.A composition according to any one of claims 1 to 7, 10 and 11, or a pharmaceutical preparation as claimed in any one of claims 8-11 for use as defined in said claims, wherein the individual suffering from DOA , at least one mutation of at least one OPA gene selected from the group consisting of OPA1, OPA2, OPA3, OPA4, OPA5, OPA6 and OPA7. 13. Sestavek ali farmacevtski pripravek po zahtevku 12, za uporabo, kot je definirano v omenjenem zahtevku, kjer ima posameznik, ki trpi zaradi DOA, vsaj eno mutacijo v vsaj OPA1 genu.A composition or pharmaceutical preparation according to claim 12 for use as defined in the claim wherein the individual suffering from DOA has at least one mutation in at least the OPA1 gene. 14. Sestavek ali farmacevtski pripravek po kateremkoli od zahtevkov 1 do 13, za uporabo, kot je definirano v omenjenih zahtevkih, kjer ima posameznik enega ali več simptomov, izbranih iz skupine, ki jo sestavljajo: izguba vidne ostrine, izguba osrednjega vida, poslabšanje barvnega vida, centrocecalni skotomi, časovna bledica optičnega diska, cirkulacija telangiektatska mikroangiopatija, varčevanje odziva pupčarske svetlobe, otekanje plasti mrežničnega vlakna okrog diska (psevdoedem) in optična atrofija.A composition or pharmaceutical preparation according to any one of claims 1 to 13 for use as defined in said claims wherein the individual has one or more symptoms selected from the group consisting of: loss of visual acuity, loss of central vision, deterioration in color vision, centrocereal scots, temporal paleness of the optical disc, circulating telangiectic microangiopathy, saving the umbilical response, swelling of the retinal layer around the disc (pseudo-edema), and optical atrophy.
SI201031630T 2009-04-28 2010-04-27 Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones SI2424495T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21479509P 2009-04-28 2009-04-28
US31873310P 2010-03-29 2010-03-29
EP10715650.7A EP2424495B1 (en) 2009-04-28 2010-04-27 Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
PCT/US2010/032624 WO2010126911A1 (en) 2009-04-28 2010-04-27 Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones

Publications (1)

Publication Number Publication Date
SI2424495T1 true SI2424495T1 (en) 2018-04-30

Family

ID=42244195

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201031630T SI2424495T1 (en) 2009-04-28 2010-04-27 Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones

Country Status (15)

Country Link
US (3) US20100273894A1 (en)
EP (2) EP2424495B1 (en)
JP (3) JP2012525399A (en)
BR (1) BRPI1013376A8 (en)
CA (1) CA2777479C (en)
DK (1) DK2424495T3 (en)
EA (1) EA031126B1 (en)
ES (1) ES2662051T3 (en)
HU (1) HUE037574T2 (en)
MX (1) MX336800B (en)
NO (1) NO2424495T3 (en)
PL (1) PL2424495T3 (en)
PT (1) PT2424495T (en)
SI (1) SI2424495T1 (en)
WO (1) WO2010126911A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514461B2 (en) 2003-09-19 2009-04-07 Edison Pharmaceuticals, Inc. Chroman derivatives
CA2610152C (en) * 2005-06-01 2018-04-10 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
EP3733642B1 (en) 2007-11-06 2024-05-08 PTC Therapeutics, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
EA023618B1 (en) 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. (HET)ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
JP5710277B2 (en) 2008-03-05 2015-04-30 エジソン ファーマシューティカルズ， インコーポレイテッド 2-Substituted-p-quinone derivatives for the treatment of oxidative stress diseases
EP2303824B1 (en) 2008-06-25 2015-03-25 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US10039722B2 (en) 2008-10-14 2018-08-07 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
SI2963006T1 (en) 2008-10-28 2019-01-31 Bioelectron Technology Corporation Composition containing alpha-tocotrienol quinone,and intermediates thereof
EP2424495B1 (en) 2009-04-28 2018-01-17 Bioelectron Technology Corporation Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
WO2011025785A1 (en) * 2009-08-26 2011-03-03 Edison Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia
CA2797644A1 (en) * 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
US9114120B2 (en) 2010-11-22 2015-08-25 Sigma-Tau Industrie Farmaceutiche Riunite, S.P.A. Therapeutical method for the treatment of the Leber optic neuropathy
WO2012174286A1 (en) * 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
PT2729004T (en) * 2011-07-06 2020-06-08 Ptc Therapeutics Inc Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones
EP2734512B1 (en) 2011-07-19 2019-11-20 Bioelectron Technology Corporation Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
JP6238977B2 (en) 2012-06-29 2017-11-29 ラオフ・レキク Angiotensin converting enzyme inhibitors for the treatment of optic neuropathy or congenital optic atrophy
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
EP2970158B1 (en) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
WO2015103577A1 (en) * 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Methods and compositions for preventing or treating dominant optic atrophy
BR112017012988B1 (en) 2014-12-16 2023-10-03 Ptc Therapeutics, Inc POLYMORAPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2- METHYL-4- (2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL) BUTANAMIDE
CN107820430A (en) * 2015-06-05 2018-03-20 瓦尔德西布伦大学医院基金会研究所 The treatment of mitochondrial disease
US10745371B2 (en) 2015-12-16 2020-08-18 Ptc Therapeutics, Inc. Methods for enriching alpha-tocotrienol from mixed tocol compositions
MX2018007389A (en) 2015-12-17 2018-08-15 Bioelectron Tech Corp Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders.
KR20210076041A (en) * 2018-10-11 2021-06-23 임브리아 파마슈티칼스, 인크. Compositions and methods for the treatment and prevention of Leber's hereditary optic neuropathy
RU2704013C1 (en) * 2019-04-18 2019-10-23 ФГБНУ "НИИ глазных болезней" Method of correction of oxidative stress in leber's hereditary optic neuropathy
CN112385783B (en) 2020-10-10 2022-07-05 南京农业大学 Baking method for controlling content of polycyclic aromatic hydrocarbon in charcoal-baked meat

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4875564A (en) 1972-01-08 1973-10-11
JPS4988862A (en) 1972-12-29 1974-08-24
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
JPH0788376B2 (en) 1986-09-02 1995-09-27 エーザイ株式会社 Process for producing optically active α-tocotrienol
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
JP2685785B2 (en) 1988-03-11 1997-12-03 エーザイ株式会社 Method for producing optically active α-tocotrienol
EP0333472B1 (en) 1988-03-16 1997-10-08 PALM OIL RESEARCH & DEVELOPMENT BOARD Production of high concentration tocopherols and tocotrienols from palm oil by-products
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5157132A (en) 1990-05-18 1992-10-20 Carotech Associates Integrated process for recovery of carotenoids and tocotrienols from oil
US5591772A (en) 1991-11-22 1997-01-07 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ES2084722T3 (en) 1990-05-29 1996-05-16 Boston Ocular Res COMPOSITION FOR DRY EYE TREATMENT.
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
US5318993A (en) * 1993-04-16 1994-06-07 Bristol-Myers Squibb Company Antihyperlipidemic benzoquinones
CN1129400A (en) 1994-05-06 1996-08-21 阿尔康实验室公司 Use of vitamin E. Tocopheryl derivatives in ophthalmic compositions
SI0801564T1 (en) 1994-12-28 2002-08-31 Janssen Pharmaceutica N.V. Use of nebivolol as an anti-atherogenic
US6232060B1 (en) 1996-01-19 2001-05-15 Galileo Laboratories, Inc. Assay system for anti-stress agents
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
US6224717B1 (en) 1998-01-29 2001-05-01 Eastman Chemical Company Methods for separating a tocotrienol from a tocol-containing mixture and compositions thereof
WO2000078296A2 (en) 1999-06-17 2000-12-28 Basf Aktiengesellschaft Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
US6395915B1 (en) 1999-09-10 2002-05-28 Technikrom, Inc. Method for producing purified tocotrienols and tocopherols using liquid chromatography
US6528042B1 (en) 1999-10-08 2003-03-04 Galileo Laboratories, Inc. Compositions of flavonoids for use as cytoprotectants and methods of making and using them
US6426362B1 (en) 1999-10-08 2002-07-30 Galileo Laboratories, Inc. Formulations of tocopherols and methods of making and using them
MY127451A (en) 1999-11-04 2006-12-29 Malaysian Palm Oil Board A method of chromatographic isolation for vitamin e isomers
DE10034233A1 (en) 2000-07-14 2002-01-24 Basf Ag Tocotrienolquinone-cyclization
GB0023555D0 (en) * 2000-09-26 2000-11-08 Inst Of Ophthalmology Improvements in and relating to treatments for eye disease
AU2002239748A1 (en) 2000-12-15 2002-06-24 Galileo Laboratories, Inc. Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
US7034054B2 (en) 2000-12-15 2006-04-25 Galileo Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
US6838104B2 (en) 2000-12-20 2005-01-04 Archer Daniels Midland Company Process for the production of tocotrienols
US6608196B2 (en) 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
US7119117B2 (en) 2001-08-21 2006-10-10 Galileo Pharmaceuticals, Inc. Tocopherol enriched compositions and amelioration of inflammatory symptoms
AU2002352726A1 (en) 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
US6667330B2 (en) 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
US7078541B2 (en) 2002-02-07 2006-07-18 Galileo Pharmaceuticals, Inc. Benzofuran derivatives
US6653346B1 (en) 2002-02-07 2003-11-25 Galileo Pharmaceuticals, Inc. Cytoprotective benzofuran derivatives
DE60211875T2 (en) 2002-07-01 2006-10-26 Santhera Pharmaceuticals (Schweiz) Ag Screening methods and compounds for the treatment of Friedreich ataxia
US7491312B2 (en) 2002-10-30 2009-02-17 Edison Pharmaceuticals, Inc. Identifying therapeutic compounds based on their physical-chemical properties
US7015243B2 (en) * 2003-08-28 2006-03-21 Allergan, Inc. Cyclohexyl prostaglandin analogs as EP4-receptor agonists
US7514461B2 (en) * 2003-09-19 2009-04-07 Edison Pharmaceuticals, Inc. Chroman derivatives
WO2005032478A2 (en) * 2003-10-01 2005-04-14 Yasoo Health, Inc. Treatment for diabetic microvascular and macrovascular complications
WO2005035491A2 (en) 2003-10-10 2005-04-21 Yasoo Health, Inc. PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND
WO2005090602A2 (en) 2004-03-18 2005-09-29 Sucampo Ag Method for diagnosing or predicting susceptibility to optic nueropathy
DE602004022523D1 (en) 2004-07-02 2009-09-24 Novagali Pharma Sa Use of emulsions for intra- and periocular injection
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
EP1885353B1 (en) 2005-04-22 2015-01-07 Elizabeth Stuart Use of vitamin e tocotrienols for the inhibition of intracellularly obligate pathogen chlamydia
CA2610152C (en) 2005-06-01 2018-04-10 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
PL1933821T3 (en) 2005-09-15 2021-01-11 Ptc Therapeutics, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2007037849A2 (en) 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
EP1986636B1 (en) * 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
US20100056429A1 (en) 2007-01-10 2010-03-04 Miller Guy M Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
WO2008157747A1 (en) 2007-06-21 2008-12-24 The Jackson Laboratory Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
EP2170374A2 (en) * 2007-07-03 2010-04-07 Andreas Reichert Method for treating diseases related to mitochondrial dysfunction
CN101827523A (en) 2007-08-16 2010-09-08 马库赛特公司 Formulations for treatment of ocular diseases or conditions
US8075909B2 (en) 2007-09-04 2011-12-13 University Of Florida Research Foundation, Incorporated Contact lens based bioactive agent delivery system
EP3733642B1 (en) 2007-11-06 2024-05-08 PTC Therapeutics, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
US20100266591A1 (en) 2008-01-07 2010-10-21 Peter Bugelski Method of treating erythropoietin hyporesponsive anemias
EA023618B1 (en) 2008-01-08 2016-06-30 Эдисон Фармасьютикалз, Инк. (HET)ARYL-p-QUINONE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
WO2009111543A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments with redox-active therapeutics
JP5710277B2 (en) 2008-03-05 2015-04-30 エジソン ファーマシューティカルズ， インコーポレイテッド 2-Substituted-p-quinone derivatives for the treatment of oxidative stress diseases
US20110142834A1 (en) 2008-05-15 2011-06-16 Edison Pharmaceuticals, Inc. Treatment of hearing and balance impairments using compounds having erythropoietin activity
US20090291092A1 (en) 2008-05-22 2009-11-26 Miller Guy M Treatment of mitochondrial diseases with an erythropoietin mimetic
EP2303824B1 (en) 2008-06-25 2015-03-25 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
US20100010100A1 (en) 2008-07-09 2010-01-14 Hinman Andrew W Dermatological compositions with anti-aging and skin even-toning properties
WO2010014361A1 (en) 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Naphthoquinone compositions with anti-aging, anti- inflammatory and skin even-toning properties
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
US8722728B2 (en) 2008-10-09 2014-05-13 Ramscor, Inc. Composition and method for treating dry eye syndrome
US10039722B2 (en) 2008-10-14 2018-08-07 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
SI2963006T1 (en) 2008-10-28 2019-01-31 Bioelectron Technology Corporation Composition containing alpha-tocotrienol quinone,and intermediates thereof
US20120136048A1 (en) 2009-04-28 2012-05-31 Miller Guy M Topical, periocular, or intraocular use of tocotrienols for the treatment of ophthalmic diseases
US20100273892A1 (en) 2009-04-28 2010-10-28 Miller Guy M Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
EP2424495B1 (en) 2009-04-28 2018-01-17 Bioelectron Technology Corporation Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
US20120122969A1 (en) 2009-06-25 2012-05-17 Ampere Life Sciences, Inc. Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts
WO2011025785A1 (en) 2009-08-26 2011-03-03 Edison Pharmaceuticals, Inc. Methods for the prevention and treatment of cerebral ischemia
WO2011041452A2 (en) 2009-10-01 2011-04-07 Ampere Life Sciences, Inc. Mouse model for identifying compounds for the treatment of oxidative stress
CA2797644A1 (en) 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
WO2011113018A1 (en) 2010-03-12 2011-09-15 Ampere Life Sciences, Inc. Measurement and control of biological time
AU2011238525A1 (en) 2010-04-06 2012-11-08 Edison Pharmaceuticals, Inc. Treatment of Ataxia Telangiectasia
SG10201801321XA (en) 2010-04-27 2018-04-27 Bioelectron Tech Corp Formulations of quinones for the treatment of ophthalmic diseases
WO2012009271A1 (en) 2010-07-14 2012-01-19 Penwest Pharmaceuticals Co. Methods of providing anticoagulation effects in subjects
MX2013001469A (en) 2010-08-06 2013-05-14 Edison Pharmaceuticals Inc Treatment of mitochondrial diseases with naphthoquinones
EP2601168A4 (en) 2010-08-06 2013-12-04 Ampere Life Sciences Inc Treatment of mitochondrial diseases with vitamin k
US20120295985A1 (en) 2010-11-19 2012-11-22 Miller Guy M Methods for improving blood glucose control
WO2012154613A1 (en) 2011-05-06 2012-11-15 Edison Pharmaceuticals, Inc. Improved process for the preparation of d-alpha-tocotrienol from natural extracts
WO2012170773A1 (en) 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
WO2012174286A1 (en) 2011-06-14 2012-12-20 Edison Pharmaceuticals, Inc. Catechol derivatives for treatment of oxidative stress diseases
WO2013006736A1 (en) 2011-07-06 2013-01-10 Edison Pharmaceuticals, Inc Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
PT2729004T (en) 2011-07-06 2020-06-08 Ptc Therapeutics Inc Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones
EP2734512B1 (en) 2011-07-19 2019-11-20 Bioelectron Technology Corporation Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
CA2902506A1 (en) 2013-03-08 2014-09-12 Unilever Plc Resorcinol compounds for dermatological use
US20140275045A1 (en) 2013-03-15 2014-09-18 Edison Pharmaceuticals, Inc. Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
EP2970158B1 (en) 2013-03-15 2019-02-20 BioElectron Technology Corporation Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
CA2912871A1 (en) 2013-05-31 2014-12-04 Edison Pharmaceuticals, Inc. Carboxylic acid derivatives for treatment of oxidative stress disorders

Also Published As

Publication number Publication date
MX336800B (en) 2016-02-02
US20100273894A1 (en) 2010-10-28
JP2012525399A (en) 2012-10-22
EP3332766A1 (en) 2018-06-13
JP2015028084A (en) 2015-02-12
BRPI1013376A8 (en) 2017-07-11
US10195161B2 (en) 2019-02-05
DK2424495T3 (en) 2018-04-30
BRPI1013376A2 (en) 2017-03-21
PT2424495T (en) 2018-03-13
US20140039065A1 (en) 2014-02-06
WO2010126911A1 (en) 2010-11-04
EP2424495A1 (en) 2012-03-07
EA201101575A1 (en) 2012-04-30
ES2662051T3 (en) 2018-04-05
EA031126B1 (en) 2018-11-30
PL2424495T3 (en) 2018-06-29
NO2424495T3 (en) 2018-06-16
CA2777479C (en) 2017-10-17
EP2424495B1 (en) 2018-01-17
MX2011011309A (en) 2011-11-18
JP2016216506A (en) 2016-12-22
US20170119695A1 (en) 2017-05-04
HUE037574T2 (en) 2018-09-28
US9370496B2 (en) 2016-06-21
CA2777479A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
SI2424495T1 (en) Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
JP2012525399A5 (en)
US20220071949A1 (en) Combinations of cannabinoids and n-acylethanolamines
JP2012525398A5 (en)
US8735377B1 (en) Methods of treating herpes zoster
EP2785328B1 (en) Novel slow-releasing ophthalmic compositions comprising povidone iodine
US20070207116A1 (en) Antioxidant compositions for the eye
US9119827B2 (en) Ophthalmic composition
KR20220044558A (en) External preparation containing cannabidiol, preparation method of composition, and use thereof
PL212457B1 (en) Method of treating middle ear infections
US20080318970A1 (en) Treatment of Infectious Diseases
CA2547852A1 (en) Agents for treatment of glaucomatous retinopathy and optic neuropathy
JP5345744B1 (en) Retinal disease prevention, amelioration, or treatment
CA3197374A1 (en) Ophthalmic composition
CA3164309A1 (en) Treatment of neurological disorders with avermectins
WO1997025036A1 (en) Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of atrophy of skin and/or mucous membranes
JP2013213050A (en) Ophthalmic composition containing geranylgeranylacetone
EP2271334B1 (en) Methods of treating fibrotic disorders
US20240269151A1 (en) Nasal sleep formulation
Velpandian et al. Comparative evaluation of possible ocular photochemical toxicity of fluoroquinolones meant for ocular use in experimental models
Lixi et al. Marine Natural Products Rescuing the Eye: A Narrative Review
WO2019109150A1 (en) Methods of treating agitation
JP2852607B2 (en) Dry eye treatment
JPH01224321A (en) Ophthalmic preparation
EP3171873B1 (en) Composition comprising an ester of alpha-tocopherol for prevention and treatment of allergic rhinitis